IFW

Rev 2/06 Rev 2/06 THE UNITED THE

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application

Andrius Kazlauskas et al.

Application No.

10/589,687

Filed

August 17, 2006

Confirmation No.

9909

For

DIAGNOSIS OR TREATMENT OF ENDOTHELIAL CELL

DYSFUNCTION REALTED DISEASES

Examiner

Unassigned

Attorney's Docket

ERI-147XX

TC Art Unit: 1647

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Bv

Holliday C. Heine, Ph.D. Registration No. 34,346 Attorney for Applicant(s)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

It is desired to cite for the record in this application the enclosed references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

[] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above identified application. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

Application No.: 10/589,687

Filed: August 17, 2006 TC Art Unit: 1647 Confirmation No.: 9909

- [X] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
 - [] a statement under 37 CFR § 1.97(e); or
 - [] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

[] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

[] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

[] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. §

Application No.: 10/589,687

Filed: August 17, 2006

TC Art Unit: 1647 Confirmation No.: 9909

1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Where the status of the application has changed, unknown to the applicant, such that the boxes checked are no longer applicable, the Commissioner is authorized to accept this submission with any additional fees required by that change charged to Deposit Account No. 23-0804.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made. The filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited herewith is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that Applicant(s) is(are) unable to provide an affidavit under 37 CFR §1.131 swearing back of such information.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

Application No.: 10/589,687

Filed: August 17, 2006

TC Art Unit: 1647

Confirmation No.: 9909

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

ANDRIUS KAZLAUSKAS ET AL.

Holliday C. Helne, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290 Telecopier: (617) 451-0313

HCH/raw Enclosure 342077.1



Date: September 28, 2006 Page 1 of 1

U.S. DEFURIDENT OF COMMERCE						ATTY. DOCKET NO.		APPLICATION NO.			
(REV. 05/05) PATENT AND TRADEMARK OFFICE											
						ERI-147XX		10/589,687			
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION											
(Use several sheets if necessary)											
						APPLICANT:					
						Andrius Kazlauzkas et al.					
						FILING DATE		TC ART UNIT			
		· · · · · · · · · · · · · · · · · · ·				August 17, 2	2006	1647			
		,	U.S. PATENT I	OCUME	NT	S		,			
EXAMINER		DOCUMENT NUMBER	PUBLICATION/		N.	AME	CLASS	SUBCLASS	FILING DATE		
INITIAL			ISSUE DATE								
		US									
		US									
		US									
		US									
			FOREIGN PATEN	T DOCUM	ME	NTS	ł	l			
		DOCUMENT NUMBER	DATE		COUNTRY		CLASS	SUBCLASS	TRANSI	LATION	
		i i							YES	NO	
											
		OTHER DOCUM	IENTS (including Au	thor. Title.	Da	te. Pertinent Pas	l ges. etc.)				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) Lei et al., "Heat Shock Protein 90 Alpha-Dependent Translocation of Annexin II to the Surface of Endothelial Cells											
		Modulates Plasmin Activity in the Diabetic Rat Aorta", Circulation Research, Vol. 94, pp.902-909, (2004).									
		Hennig et al., "High-Energy Diets, Fatty Acids and Endothelial Cell Function: Implication for Atherosclerosis", <i>Journal of American College of Nutrition</i> , Vol. 20, No. 2, pp. 97-105, (2001).									
		Lentz, S. R., "Does Homocysteine Promote Artherosclerosis", <i>Artherioscler. Thromb. Vasc. Biol.</i> , Vol. 21, pp. 1385-1386, (2001). Guerci et al., "Endothelial Dysfunction and Type 2 Diabetes", Diabetes Metab., Vol. 27, pp. 425-434, (2001).									
		Romeo et al., "Profilin Acts Downstream of LDL to Mediate Diabetic Endothelial Cell Dysfunction", FASEB Journal, Feb (2004).									
EXAMINER D					AT	ATE CONSIDERED					
		itial if citation considered, whether or no clude copy of this form with next commu			M	PEP 609; Draw	line through	citation if not in	conforman	ice and	
not considered.		erade topy or and form with next commit	uppneam.								